rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2025-3243MACRPXrpcardio-3243Research ArticleNEWSНОВОСТИThe results of recent randomized controlled trials presented at the congress of the European Society of Cardiology: is everything so simple in evaluating their results?Результаты недавних рандомизированных контролируемых исследований, доложенных на очередном конгрессе Европейского общества кардиологов: все ли так просто в оценке их результатов?https://orcid.org/0000-0002-7717-4362МарцевичС. Ю.MartsevichS. Yu.

Марцевич Сергей Юрьевич

Москва

Sergey Yu. Martsevich

Moscow

sergeymartsevich@mail.ruФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииРоссияNational Medical Research Center for Therapy and Preventive Medicine, Moscow, RussiaRussian Federation202514012026215492497Copyright © Martsevich S.Y., 20262026Марцевич С.Ю.Martsevich S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/3243

The results of randomized controlled trials (RCTs) presented at the recent ESC Congress are being analyzed. A number of RCTs with similar objectives have yielded formally opposite results. This primarily concerns the effectiveness of beta-blockers in modern conditions after a myocardial infarction, as well as the possibility of replacing dual antiplatelet therapy with monotherapy with prasugrel or ticagrelor after a myocardial infarction. However, a thorough analysis of the methodological features of these RCTs reveals that the discrepancies between them are not significant. It is anticipated that the results of several RCTs may be challenging to integrate into the CR.

Анализируются результаты рандомизированных контролируемых исследований (РКИ), представленных на прошедшем Конгрессе Европейского общества кардиологов. Ряд РКИ, в которых ставились похожие задачи, формально дали противоположные результаты. Это касается в первую очередь эффективности в современных условиях бета-блокаторов после перенесенного инфаркта миокарда, а также возможности замены двойной антиагрегантной терапии на монотерапию прасугрелем или тикагрелором после перенесенного инфаркта миокарда. Однако тщательный анализ методических особенностей проведения этих РКИ показывает, что противоречия между ними не столь существенны. Предполагается, что результаты ряда РКИ будет непросто интегрировать в клинические рекомендации.

недавние рандомизированные контролируемые исследованиярезультатысердечно-сосудистые препаратыоценка эффекта с позиций доказательной медициныанализ противоречий в результатахrecent randomized controlled studiesresultscardiovascular drugsassessment of effect from the standpoint of evidence-based medicineanalysis of discrepancies in resultsReferencesBavendiek U, Großhennig A, Schwab J, et al.; DIGIT-HF Study Group. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2025. DOI:10.1056/NEJMoa2415471. Epub ahead of print.Bavendiek U, Großhennig A, Schwab J, et al.; DIGIT-HF Study Group. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2025. DOI:10.1056/NEJMoa2415471. Epub ahead of print.van Veldhuisen DJ, Rienstra M, Mosterd A, et al.; DECISION Investigators and Committees. Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial. Eur J Heart Fail. 2024;26(10):2223-30. DOI:10.1002/ejhf.3428.van Veldhuisen DJ, Rienstra M, Mosterd A, et al.; DECISION Investigators and Committees. Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial. Eur J Heart Fail. 2024;26(10):2223-30. DOI:10.1002/ejhf.3428.Cleland JGF, McMurray JJV, Freemantle N. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;391(1):94. DOI:10.1056/NEJMc2406095.Cleland JGF, McMurray JJV, Freemantle N. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;391(1):94. DOI:10.1056/NEJMc2406095.Watanabe H, Ozasa N, Morimoto T, et al.; CAPITAL-RCT investigators. Longterm use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One. 2018;13(8):e0199347. DOI:10.1371/journal.pone.0199347.Watanabe H, Ozasa N, Morimoto T, et al.; CAPITAL-RCT investigators. Longterm use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One. 2018;13(8):e0199347. DOI:10.1371/journal.pone.0199347.Munkhaugen J, Kristensen AMD, Halvorsen S, et al.; BETAMI–DANBLOCK Investigators. Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. N Engl J Med. 2025. DOI:10.1056/NEJMoa2505985. Epub ahead of print.Munkhaugen J, Kristensen AMD, Halvorsen S, et al.; BETAMI–DANBLOCK Investigators. Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. N Engl J Med. 2025. DOI:10.1056/NEJMoa2505985. Epub ahead of print.Ibanez B, Latini R, Rossello X, et al.; REBOOT-CNIC Investigators. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. N Engl J Med. 2025. DOI:10.1056/NEJMoa2504735. Epub ahead of print.Ibanez B, Latini R, Rossello X, et al.; REBOOT-CNIC Investigators. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. N Engl J Med. 2025. DOI:10.1056/NEJMoa2504735. Epub ahead of print.Lemesle G, Didier R, Steg PG, et al.; AQUATIC Trial Investigators. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. N Engl J Med. 2025. DOI:10.1056/NEJMoa2507532. Epub ahead of print.Lemesle G, Didier R, Steg PG, et al.; AQUATIC Trial Investigators. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. N Engl J Med. 2025. DOI:10.1056/NEJMoa2507532. Epub ahead of print.Tarantini G, Honton B, Paradies V, et al.; TARGET-FIRST Investigators. Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction. N Engl J Med. 2025. DOI:10.1056/NEJMoa2508808. Epub ahead of print.Tarantini G, Honton B, Paradies V, et al.; TARGET-FIRST Investigators. Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction. N Engl J Med. 2025. DOI:10.1056/NEJMoa2508808. Epub ahead of print.Guimarães PO, Franken M, Tavares CAM, et al.; NEO-MINDSET Trial Investigators. Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. N Engl J Med. 2025. DOI:10.1056/NEJMoa2507980. Epub ahead of print.Guimarães PO, Franken M, Tavares CAM, et al.; NEO-MINDSET Trial Investigators. Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. N Engl J Med. 2025. DOI:10.1056/NEJMoa2507980. Epub ahead of print.Jøns C, Zheng C, Winsløw UCG, et al.; POTCAST Study Group. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. N Engl J Med. 2025 Aug 29. DOI:10.1056/NEJMoa2509542. Epub ahead of print.Jøns C, Zheng C, Winsløw UCG, et al.; POTCAST Study Group. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. N Engl J Med. 2025 Aug 29. DOI:10.1056/NEJMoa2509542. Epub ahead of print.Flack JM, Azizi M, Brown JM, et al.; BaxHTN Investigators. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025. DOI:10.1056/NEJMoa2507109. Epub ahead of print.Flack JM, Azizi M, Brown JM, et al.; BaxHTN Investigators. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025. DOI:10.1056/NEJMoa2507109. Epub ahead of print.Garcia-Pavia P, Maron MS, Masri A, et al.; MAPLE-HCM Investigators. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025. DOI:10.1056/NEJMoa2504654. Epub ahead of print.Garcia-Pavia P, Maron MS, Masri A, et al.; MAPLE-HCM Investigators. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025. DOI:10.1056/NEJMoa2504654. Epub ahead of print.Desai MY, Owens AT, Abraham T, et al.; ODYSSEY-HCM Investigators. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025. DOI:10.1056/NEJMoa2505927. Epub ahead of print.Desai MY, Owens AT, Abraham T, et al.; ODYSSEY-HCM Investigators. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025. DOI:10.1056/NEJMoa2505927. Epub ahead of print.Bergmark BA, Marston NA, Prohaska TA, et al.; Essence–TIMI 73b Investigators. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. N Engl J Med. 2025. DOI:10.1056/NEJMoa2507227. Epub ahead of print.Bergmark BA, Marston NA, Prohaska TA, et al.; Essence–TIMI 73b Investigators. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. N Engl J Med. 2025. DOI:10.1056/NEJMoa2507227. Epub ahead of print.Johansen ND, Modin D, Loiacono MM, et al. High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. N Engl J Med. 2025. DOI:10.1056/NEJMoa2509907. Epub ahead of print.Johansen ND, Modin D, Loiacono MM, et al. High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. N Engl J Med. 2025. DOI:10.1056/NEJMoa2509907. Epub ahead of print.

The authors declare that there are no conflicts of interest present.